Neuroblastoma (NB) is the most frequently-occurring extracranial childhood tumor. It is classified as an embryonal neuroendocrine tumor, originating from neural crest progenitor cells. Hence, it can occur anywhere along the sympathetic nervous system, including the superior cervical, paraspinal, and celiac ganglia; the majority arise in the adrenal glands. Due to the high variability in its presentation, clinical signs and symptoms at presentation can range from benign palpable mass with distension to major illness from substantial tumor spread. Although overall increases in five-year event-free survival have been reported, subgroup-specific analysis of mortality has revealed discordance between the high cure rates for the more benign low-risk forms and little improvement in the high-risk groups. Thus, the impetus for the development of targeted therapeutics in the intensive management of high-risk groups is strong.
Risk factors for the acquisition of mutations in key genes leading to neuroblastoma have yet to be identified although exposures during conception and pregnancy are a topic of investigation. Neuroblastoma can develop either sporadically or be transmitted in the germline. Most familial cases of neuroblastoma occur due to the inheritance of highly penetrant mutations in either the ALK or PHOX2B genes.  A small subset of familial NB demonstrates autosomal dominant inheritance. Although up to 15% of sporadic cases of neuroblastoma arise from mutations in ALK, more common transforming mutations involve polymorphisms in BARD1 (2q35), LIN28B (6q16.3), or FLJ22536 (6p22.3). Cytogenetic aberrations can further include loss of chromosome 1p and 11q, copy number variation in 1q21, and gain of 17q. Notably, amplification of MYCN oncogene is seen in approximately 25% of patients and is associated with the poorest prognosis; 17q gain and 1p loss correlate with MYCN amplification.
Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture.
Given the wide areas populated by neural crest cells, neuroblastoma can present in the neck, chest, abdomen, or pelvis. With the most frequent site of origin being the adrenal medulla, patients often present with a solid abdominal mass. With involvement of the superior cervical ganglia, aside from a neck mass, Horner syndrome (ptosis, miosis, anhydrosis) can be observed. If tumor involves the spinal cord, cord compression or paralysis may be seen. Furthermore, tumor behavior can range from spontaneous regression to widespread dissemination at presentation. With over half of all neuroblastoma patients having hematogenous spread at diagnosis, the disease can involve the bone and bone marrow (56% and 71%, respectively), followed by lymph nodes (31%), and lungs (3%). Non-specific clinical signs include fever, weight loss, and fatigue. Thus, signs and symptoms, which can range from an asymptomatic palpable mass to significant critical illness, are highly variable and dependent upon factors now linked with prognosis.
The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Children’s Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy :
However, COG classification of neuroblastoma has differed from the European SIOPEN and other cooperative groups. In 2004, the International Neuroblastoma Risk Group (INRG), a task force of pediatric neuroblastoma experts worldwide, met with the primary aim of developing a consensus approach to neuroblastoma risk stratification pre-treatment. Using patient age, tumor stage, tumor grade and differentiation, tumor histology, MYCN amplification, cytogenetic aberrations in 11q, and DNA ploidy, the group defined 16 pre-treatment groups broadly divisible into four prognostic subgroups based on five-year event-free survival (EFS):
Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.
Diagnostic evaluation relies not only on a careful history and physical, but also on biochemical, histologic, and radiographic analyses. Histologic confirmation is required to establish a diagnosis of neuroblastoma. Histologically, small round pale blue cells, known as Homer-Wright pseudorosettes, can be seen; these are similarly seen in Wilm's tumor and Ewing sarcoma, leading to their common group categorization as small blue cell tumors. If a biopsy sample is tumor-positive, DNA ploidy and MYCN gene status are further evaluated. Since neuroblastoma cells originate from neural crest cells destined to differentiate into sympathetic peripheral neurons, cells often produce catecholamines; break-down products of these catecholamines are homovanillic acid (HVA) and vanillylmandelic acid (VMA). Thus, in over 90% of neuroblastoma, elevation in these catecholamine breakdown products in urine is diagnostic. Preliminary imaging is preferentially conducted with MRI for good resolution and surgical excision planning. Further exploiting sympathetic neuronal uptake of mIBG (metaiodobenzylguanidine), due to its analogous nature to norepinephrine, the extent of neuroblastoma metastasis can be delineated with an mIBG scan with high accuracy and quality. To complete tumor staging, bone marrow biopsies are required. Of note, common paraneoplastic conditions associated with neuroblastoma include opsoclonus-myoclonus syndrome and intractable secretory diarrhea due to vasoactive intestinal peptide (VIP) secretion.
Given the heterogeneity in tumor location, grade, and stage at diagnosis, treatment modalities include simple observation, surgical resection, chemotherapy, radiation therapy, stem cell transplantation, and immunotherapy. Patients with low-risk NB have localized tumor, some (infants) with a high propensity for spontaneous tumor regression. Thus, children with small tumors (less than 5 cm) can simply be observed with imaging done every six to 12 weeks to monitor tumor growth, thus avoiding surgery in the young infant altogether. For larger, localized tumors, in patients past infancy, surgical resection is pursued. For patients younger than 18 months of age, the observational approach is currently under international investigation by COG (NCT02176967) and SIOPEN (NCT01728155) cooperative groups. For children who present with symptoms, limited chemotherapy is given without surgical palliation or radiation therapy. The intermediate-risk group presents with localized metastasis, i.e., to the lymph node or bone marrow (in infants). They are usually managed with chemotherapy alone and possible surgical resection if able. The high-risk group has the worst prognosis and presents with widespread metastatic disease to the bone marrow, bone, lungs, and liver. They receive induction chemotherapy to reduce tumor burden at both the primary and metastatic locations, followed by maximal surgical resection, followed by myeloablative chemotherapy and stem-cell transplantation. After that, patients are managed on a combination of maintenance chemotherapy and immunotherapy. A monoclonal antibody, dinutuximab (Unituxin), that attaches to a carbohydrate molecule (GD2) on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Dinutuximab treatment is reported to improve the two-year event-free survival of high-risk neuroblastoma patients from 46% to 66%.
Neuroblastoma is a rare abdominal tumor in young children. However, if the diagnosis is missed, the tumor is fatal. Hence, the diagnosis and treatment of neuroblastoma are best managed by a multidisciplinary team that includes a pediatrician, a pediatric surgeon, oncologist, radiation therapist, social workers, and NICU nurses. The tumor may occur anywhere along the sympathetic chain and can be mistaken for a Wilms tumor. Over the past decade the survival of these patients has slightly improved for early-stage lesions, but for late stages the survival is abysmal. Thus, the impetus for the development of targeted therapeutics in the intensive management of high-risk groups is strong.
|||Matthay KK,Maris JM,Schleiermacher G,Nakagawara A,Mackall CL,Diller L,Weiss WA, Neuroblastoma. Nature reviews. Disease primers. 2016 Nov 10; [PubMed PMID: 27830764]|
|||Maris JM, Recent advances in neuroblastoma. The New England journal of medicine. 2010 Jun 10; [PubMed PMID: 20558371]|
|||Maris JM,Hogarty MD,Bagatell R,Cohn SL, Neuroblastoma. Lancet (London, England). 2007 Jun 23; [PubMed PMID: 17586306]|
|||Linabery AM,Ross JA, Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008 Nov 1; [PubMed PMID: 18837040]|
|||Mossé YP,Laudenslager M,Longo L,Cole KA,Wood A,Attiyeh EF,Laquaglia MJ,Sennett R,Lynch JE,Perri P,Laureys G,Speleman F,Kim C,Hou C,Hakonarson H,Torkamani A,Schork NJ,Brodeur GM,Tonini GP,Rappaport E,Devoto M,Maris JM, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16; [PubMed PMID: 18724359]|
|||Knudson AG Jr,Strong LC, Mutation and cancer: neuroblastoma and pheochromocytoma. American journal of human genetics. 1972 Sep; [PubMed PMID: 4340974]|
|||Maris JM,Mosse YP,Bradfield JP,Hou C,Monni S,Scott RH,Asgharzadeh S,Attiyeh EF,Diskin SJ,Laudenslager M,Winter C,Cole KA,Glessner JT,Kim C,Frackelton EC,Casalunovo T,Eckert AW,Capasso M,Rappaport EF,McConville C,London WB,Seeger RC,Rahman N,Devoto M,Grant SF,Li H,Hakonarson H, Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. The New England journal of medicine. 2008 Jun 12; [PubMed PMID: 18463370]|
|||Capasso M,Devoto M,Hou C,Asgharzadeh S,Glessner JT,Attiyeh EF,Mosse YP,Kim C,Diskin SJ,Cole KA,Bosse K,Diamond M,Laudenslager M,Winter C,Bradfield JP,Scott RH,Jagannathan J,Garris M,McConville C,London WB,Seeger RC,Grant SF,Li H,Rahman N,Rappaport E,Hakonarson H,Maris JM, Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature genetics. 2009 Jun; [PubMed PMID: 19412175]|
|||Diskin SJ,Capasso M,Schnepp RW,Cole KA,Attiyeh EF,Hou C,Diamond M,Carpenter EL,Winter C,Lee H,Jagannathan J,Latorre V,Iolascon A,Hakonarson H,Devoto M,Maris JM, Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nature genetics. 2012 Oct; [PubMed PMID: 22941191]|
|||Heukamp LC,Thor T,Schramm A,De Preter K,Kumps C,De Wilde B,Odersky A,Peifer M,Lindner S,Spruessel A,Pattyn F,Mestdagh P,Menten B,Kuhfittig-Kulle S,Künkele A,König K,Meder L,Chatterjee S,Ullrich RT,Schulte S,Vandesompele J,Speleman F,Büttner R,Eggert A,Schulte JH, Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science translational medicine. 2012 Jul 4; [PubMed PMID: 22764207]|
|||London WB,Castleberry RP,Matthay KK,Look AT,Seeger RC,Shimada H,Thorner P,Brodeur G,Maris JM,Reynolds CP,Cohn SL, Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20; [PubMed PMID: 16116153]|
|||Althoff K,Beckers A,Bell E,Nortmeyer M,Thor T,Sprüssel A,Lindner S,De Preter K,Florin A,Heukamp LC,Klein-Hitpass L,Astrahantseff K,Kumps C,Speleman F,Eggert A,Westermann F,Schramm A,Schulte JH, A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015 Jun; [PubMed PMID: 25174395]|
|||Cohn SL,Pearson AD,London WB,Monclair T,Ambros PF,Brodeur GM,Faldum A,Hero B,Iehara T,Machin D,Mosseri V,Simon T,Garaventa A,Castel V,Matthay KK, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 10; [PubMed PMID: 19047291]|
|||LaBrosse EH,Com-Nougué C,Zucker JM,Comoy E,Bohuon C,Lemerle J,Schweisguth O, Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer research. 1980 Jun; [PubMed PMID: 7371035]|
|||Vik TA,Pfluger T,Kadota R,Castel V,Tulchinsky M,Farto JC,Heiba S,Serafini A,Tumeh S,Khutoryansky N,Jacobson AF, (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatric blood [PubMed PMID: 19185008]|
|||Kaplan SJ,Holbrook CT,McDaniel HG,Buntain WL,Crist WM, Vasoactive intestinal peptide secreting tumors of childhood. American journal of diseases of children (1960). 1980 Jan [PubMed PMID: 6101297]|
|||Brunklaus A,Pohl K,Zuberi SM,de Sousa C, Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Archives of disease in childhood. 2012 May [PubMed PMID: 21460401]|
|||Matthay KK, Stage 4S neuroblastoma: what makes it special? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jun [PubMed PMID: 9626196]|
|||Baker DL,Schmidt ML,Cohn SL,Maris JM,London WB,Buxton A,Stram D,Castleberry RP,Shimada H,Sandler A,Shamberger RC,Look AT,Reynolds CP,Seeger RC,Matthay KK, Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. The New England journal of medicine. 2010 Sep 30 [PubMed PMID: 20879880]|
|||Park JR,Bagatell R,London WB,Maris JM,Cohn SL,Mattay KK,Hogarty M, Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatric blood & cancer. 2013 Jun [PubMed PMID: 23255319]|
|||Yu AL,Gilman AL,Ozkaynak MF,London WB,Kreissman SG,Chen HX,Smith M,Anderson B,Villablanca JG,Matthay KK,Shimada H,Grupp SA,Seeger R,Reynolds CP,Buxton A,Reisfeld RA,Gillies SD,Cohn SL,Maris JM,Sondel PM, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. The New England journal of medicine. 2010 Sep 30 [PubMed PMID: 20879881]|
|||Zage PE, Novel Therapies for Relapsed and Refractory Neuroblastoma. Children (Basel, Switzerland). 2018 Oct 31 [PubMed PMID: 30384486]|
|||Bansal D,Totadri S,Chinnaswamy G,Agarwala S,Vora T,Arora B,Prasad M,Kapoor G,Radhakrishnan V,Laskar S,Kaur T,Rath GK,Bakhshi S, Management of Neuroblastoma: ICMR Consensus Document. Indian journal of pediatrics. 2017 Jun [PubMed PMID: 28367616]|